GI & Endoscopy

Robin D. Rothstein, MD, is co-medical director of the inflammatory bowel disease program at Temple University Hospital in Philadelphia.

Here are seven updates from gastroenterology companies and practices from the past week:

RDD Pharma entered into a letter of intent to acquire Naia Rare Diseases in a move to boost its gastrointestinal drug pipeline.

Finch Therapeutics and Takeda Pharmaceuticals entered into a partnership to develop a microbiome treatment for Crohn's disease, the companies announced Nov. 13.

AbbVie made the fourth largest corporate bond sale of all time when it sold $30 billion worth of bonds to partially finance its $83 billion takeover of Allergan, the Financial Times reports.

Atlanta Gastroenterology Associates took on a private equity partner in Frazier Healthcare Partners on Dec. 17, 2018, forming gastroenterology management company United Digestive in the process.

Here are five gastroenterology-focused companies that either recently began developing or launched new products:

Matthew A. Ciorba, MD, is chief of the gastroenterology division's inflammatory bowel disease program at Washington University School of Medicine in St. Louis.

Exact Sciences closed its $2.8 billion acquisition of Genomic Health Nov. 8, securing rights to Genomic's diagnostic oncology test, Oncotype DX.

Boston Medical Center is studying how Motus GI's Pure-Vu System affects bowel preparation in a clinical setting.